Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 vs JNJ-78436735 Booster in Transplant Recipients
NCT05047640Phase 3Terminated
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing BNT162b2 Group with JNJ-78436735 Group (2 arms). Primary endpoint: Percentage of Participants Who Tested Positive for IgG Antibodies to the Anti-spike Protein of SARS-CoV-2 at 1 month. Started Sep 2021; status: terminated.
02
Drugs
tozinameranAd26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05047640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047640.